Clinical Trial Results: A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating continued dosing/follow-up for patients previously exposed to poziotinib; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Poziotinib (poziotinib)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: NSCLC, Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2026-07-28